Recombinant oncolytic influenza virus expressing chemokine CCL19 and its application

By inserting the CCL19 gene into the influenza virus, the recombinant oncolytic influenza virus rFlu-PB1-CCL19 was developed, which solved the existing oncolytic virus low replication efficiency and safety problems, and achieved efficient tumor-specific infection and immune activation, significantly Inhibit colorectal cancer growth and prolong the survival of mice.

CN117660368BActive Publication Date: 2024-11-08KUNMING UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311089112.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-28
Publication Date
2024-11-08
Estimated Expiration
2043-08-28

AI Technical Summary

Technical Problem

The existing oncolytic viruses have low replication efficiency, difficulty in preparing viruses, low genetic safety and easy removal by the host in tumor treatment, which limits their clinical application, especially in the treatment of colorectal cancer.

Method used

A recombinant oncolytic influenza virus rFlu-PB1-CCL19 expressing the chemokine CCL19 was developed. By inserting the CCL19 gene into the influenza virus genome, it uses the gene plasticity and high replication ability of the influenza virus to prepare a high specific infection and Recombinant viruses that kill tumor cells, combined with the immune activation function of CCL19, enhance the immune response of the tumor microenvironment.

Benefits of technology

The recombinant oncolytic influenza virus rFlu-PB1-CCL19 has high replication efficiency in colorectal cancer cells, has obvious killing effects, is harmless to normal cells, can effectively inhibit tumor growth and prolong the survival of mice, proving that it is in tumor treatment tumor inhibition effect and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117660368B_ABST
    Figure CN117660368B_ABST
Patent Text Reader

Abstract

The present invention discloses a recombinant oncolytic influenza virus expressing chemokine CCL19 and its application. The recombinant oncolytic influenza virus provided by the present invention is to insert the human chemokine CCL19 gene into the influenza virus genome fragment, and rescue the recombinant influenza virus with replication and infection ability by reverse genetics technology, and can continuously and stably express CCL19 protein in tumor cells. The oncolytic influenza virus can recruit and activate immune cells such as T cells, macrophages, and NK cells, promote tumor antigen presentation, improve the tumor microenvironment, and achieve the purpose of tumor immunotherapy; the influenza virus strain is influenza A virus or influenza B virus; the immunotherapy tumor includes but is not limited to colorectal cancer. The recombinant influenza virus of the present invention has the advantages of strong tumor killing specificity, high effectiveness, and good safety, and can be used for the treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a recombinant oncolytic influenza virus expressing chemokine CCL19 and applications thereof. Background Art

[0002] Tumors seriously threaten human life and health. Traditional treatment methods include surgery, radiotherapy, chemotherapy, etc., but these treatments still have problems such as incurable diseases and serious toxic side effects. In the past decade, tumor immunotherapy has made great progress. By restarting and maintaining the tumor-immune cycle, the body's normal anti-tumor immunity is activated, thereby achieving the purpose of controlling and eliminating tumors. However, the immunosuppressive state in the tumor microenvironment limits the effect of tumor immunotherapy. Tumor cells mainly induce and maintain an immunosuppressive state in two ways: one is to gather immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells around the tumor, and inactivate cytotoxic T lymphocytes by secreting immunosuppressive factors, thereby forming a tumor immunosuppressive state; the other is to induce the expression of immune checkpoint molecules such as programmed death ligand 1 / programmed death 1 and cytotoxic T lymphocyte-associated antigen, leading to tumor immune escape and forming a tumor immunosuppressive microenvironment.

[0003] Oncolytic virus therapy is an important branch of tumor immunotherapy and has been fully proven to have broad application prospects in the field of tumor treatment. Oncolytic viruses are a class of natural or genetically modified viruses that can selectively infect and kill tumor cells. It mediates anti-tumor activity mainly in two ways. The first way is direct lysis, that is, the oncolytic virus selectively replicates in tumor cells, causing tumor cell lysis and necrosis, and releasing tumor-associated antigens (TAAs), destroying the tumor microenvironment immunosuppressive ecology, and inducing systemic anti-tumor immunity; secondly, through molecular biology technology, cytokines, chemokines, immune checkpoint inhibitors, etc. that enhance immune response are inserted into the oncolytic virus genome. When the recombinant oncolytic virus replicates in the host cell, the exogenous gene is expressed at the same time, which plays the role of recruiting and activating the host's CD4+ cells, CD8+T cells, NK cells and other immune cells. The activated immune cells infiltrate into the tumor microenvironment, which can effectively improve the tumor microenvironment and enhance the tumor killing effect. The oncolytic viruses that have been studied more frequently include adenovirus, herpes simplex virus type I, vaccinia virus, vesicular stomatitis virus, etc. However, these viruses have low replication efficiency and difficulty in virus preparation; viral DNA is easily integrated into the host genome, with low genetic safety; the viral particles are large and easily cleared by the host prematurely, which limits their clinical application.

[0004] Influenza virus is an excellent oncolytic virus vector. Influenza virus is a segmented RNA virus with no reverse transcriptase activity and DNA integration activity. The viral gene will not be integrated into the host genome, and the genetic safety is high. Moreover, the influenza virus hemagglutinin (HA) binding receptor N-acetylsialic acid receptor (SAR) is widely distributed on the surface of various tumor cells such as lung cancer, colorectal cancer, and prostate cancer. Therefore, influenza virus has natural infectivity to various tumor cells. At the same time, the size of influenza virus particles is between 80 and 120nm, which is moderate in size. It not only has strong immunogenicity and immunoregulatory ability, causing immunogenic death of tumor cells, but also will not be cleared by the body too early, and can exert a long-term effect. In addition, the influenza virus has strong genetic plasticity. Using the reverse genetics technology of influenza virus, the 8 gene fragments of the virus can be transformed and modified separately. The operation is simple and easy. More importantly, the influenza virus can be effectively replicated in chicken embryos. Using it as a vector to prepare oncolytic viruses can obtain greater production capacity. Therefore, modifying influenza virus to make it oncolytic virus is a new approach for anti-tumor immunotherapy.

[0005] Chemokine CCL19 is mainly expressed in T cells in peripheral lymphoid tissues and organs such as spleen and lymph nodes, while its specific receptor CCR7 is mainly distributed on the surface of mature DC cells, macrophages, NK cells, B cells and T cells. Lymphocytes can move toward central immune organs, peripheral lymph nodes, inflammatory sites, etc. through the binding of CCL19 and CCR7, and lymphocyte homing occurs. In addition, CCL19 also has the function of inducing specific anti-tumor immune responses. CCL19 highly expressed in the tumor microenvironment can specifically bind to the CCL19 / CCR7 biological axis, chemotactic immune cells including T lymphocytes, B lymphocytes, dendritic cells, macrophages, NK, etc., infiltrate into the tumor microenvironment, activate and maintain T cell homeostasis; promote the endocytosis of dendritic cells; promote the proliferation of natural killer cells, etc., improve the immunosuppressive state in the tumor microenvironment, and exert anti-tumor effects. At the same time, CCL19 can also inhibit MET / ERK / HIF-1α and other pathways by promoting the expression of miR-206 in tumor cells, inhibiting the expression of VEGFA, thereby inhibiting tumor angiogenesis and exerting an anti-tumor effect. Summary of the invention

[0006] The technical problem to be solved by the present invention is how to improve the immunotherapy effect of tumors, especially the treatment of colorectal cancer.

[0007] In order to solve the above technical problems, the present invention first provides a recombinant oncolytic influenza virus expressing chemokine CCL19, named rFlu-PB1-CCL19. The recombinant oncolytic influenza virus is ① or ②:

[0008] ① Influenza virus containing a protein called chemokine CCL19;

[0009] ②Influenza virus expressing chemokine CCL19 protein;

[0010] The CCL19 is the protein described in 1) or 2) or 3) below:

[0011] 1) The amino acid sequence of the protein is shown in SEQ ID NO: 1, and is encoded by nucleotides 2422-2652 shown in SEQ ID NO: 2;

[0012] 2) A protein derived from 1) having the same function as obtained by substituting and / or deleting and / or adding one or more amino acid residues in the amino acid sequence shown in SEQ ID NO: 1;

[0013] 3) A recombinant protein obtained by connecting a tag and / or other gene to the C-terminus and / or N-terminus of 1) or 2).

[0014] The genome of the recombinant oncolytic influenza virus is a single-stranded negative-strand, segmented RNA, and the negative-strand RNA of the recombinant oncolytic influenza virus transcribes a set of positive-strand RNAs complementary to the negative-strand RNA, and the set of positive-strand RNAs includes PB2-RNA, PB1-CCL19-RNA, HA-RNA, PA-RNA, NP-RNA, NA-RNA, M-RNA, and NS-RNA;

[0015] The PB2-RNA is a positive-strand RNA encoding the PB2 gene in the influenza virus strain;

[0016] The PB1-CCL19-RNA is a positive-strand RNA encoding the recombinant gene PB1-CCL19 according to claim 1;

[0017] The HA-RNA is a positive-strand RNA encoding the HA gene in the influenza virus strain;

[0018] The PA-RNA is a positive-strand RNA encoding the PA gene in the influenza virus strain;

[0019] The NP-RNA is a positive-strand RNA encoding the NP gene in the influenza virus strain;

[0020] The M-RNA is a positive-strand RNA encoding the M gene in the influenza virus strain;

[0021] The NA-RNA is a positive-strand RNA encoding the NA gene in the influenza virus strain;

[0022] The NS-RNA is a positive-strand RNA encoding the NS gene in the influenza virus strain;

[0023] In the above-mentioned recombinant oncolytic influenza virus, the set of positive-strand RNA may also be composed only of the PB2-RNA, the PB1-CCL19-RNA, the HA-RNA, the PA-RNA, the NP-RNA, the M-RNA, the NA-RNA and the NS-RNA.

[0024] In the above-mentioned recombinant oncolytic influenza virus, the sequence of the PB1-CCL19-RNA is a sequence obtained by inserting a hydrolyzable Linker T2A nucleotide sequence from 5'→3' before the termination codon at the 5'NCR end of the PB1 gene in the influenza virus strain, the nucleotides 2296-2358 in the sequence SEQ ID NO: 2; a CCL19 signal peptide nucleotide sequence, the nucleotides 2359-2421 in the sequence SEQ ID NO: 2; a CCL19 nucleotide sequence, the nucleotides 2422-2652 in the sequence SEQ ID NO: 2, and a nucleotide sequence of the packaging signal sequence at the 5'NCR end of the PB1 gene, the nucleotides 2653-2766 in the sequence SEQ ID NO: 2, and the other nucleotides remain unchanged.

[0025] The influenza virus strain includes but is not limited to any subtype of influenza A virus or influenza B virus.

[0026] To solve the above technical problems, the present invention also provides a method for constructing and rescuing a recombinant oncolytic influenza virus expressing CCL19, the method comprising introducing a recombinant vector pHW2000-PB2 containing a DNA molecule encoding the PB2-RNA, a recombinant vector pHW2000-PA containing a DNA molecule encoding the PA-RNA, a recombinant vector pHW2000-HA containing a DNA molecule encoding the HA-RNA, a recombinant vector pHW2000-NP containing a DNA molecule encoding the NP-RNA, a recombinant vector pHW2000-M containing a DNA molecule encoding the M-RNA, a recombinant vector pHW2000-NA containing a DNA molecule encoding the NA-RNA, a recombinant vector pHW2000-NS containing a DNA molecule encoding the NS-RNA, and a recombinant vector pHW2000-PB1-CCL19 containing a DNA molecule encoding the PB1-CCL19-RNA into packaging cells to obtain a recombinant oncolytic influenza virus expressing the chemokine CCL19.

[0027] In order to solve the above technical problems, the present invention also provides any of the following products:

[0028] (1) the genome of the recombinant oncolytic influenza virus;

[0029] (2) A set of vectors for treating tumors, i.e., vectors containing the CCL19 coding gene;

[0030] (3) A set of expression cassettes for treating tumors, i.e., an expression cassette containing the CCL19 encoding gene;

[0031] (4) a set of genes for treating tumors, namely, the coding gene of CCL19;

[0032] (5) A set of proteins for treating tumors, namely the CCL19 protein;

[0033] In order to solve the above technical problems, the present invention also provides a biological material related to the recombinant oncolytic influenza virus, wherein the biological material is any of the following products:

[0034] (1) A complete set of DNA molecules encoding the complete set of positive-strand RNA of the recombinant oncolytic influenza virus. The complete set of DNA molecules consists of a DNA molecule encoding the PB2-RNA, a DNA molecule encoding the PA-RNA, a DNA molecule encoding the PB1-CCL19-RNA, a DNA molecule encoding the NP-RNA, a DNA molecule encoding the NA-RNA, a DNA molecule encoding the HA-RNA, a DNA molecule encoding the M-RNA, and a DNA molecule encoding the NS-RNA.

[0035] (2) A complete set of recombinant vectors. The complete set of recombinant vectors consists of a recombinant vector containing a DNA molecule encoding the PB2-RNA, a recombinant vector containing a DNA molecule encoding the PA-RNA, a recombinant vector containing a DNA molecule encoding the HA-RNA, a recombinant vector containing a DNA molecule encoding the NP-RNA, a recombinant vector containing a DNA molecule encoding the M-RNA, a recombinant vector containing a DNA molecule encoding the NA-RNA, a recombinant vector containing a DNA molecule encoding the NS-RNA, and a recombinant vector containing a DNA molecule encoding the PB1-CCL19-RNA.

[0036] (3) a microorganism containing the recombinant oncolytic influenza virus;

[0037] (4) Animal cells containing the recombinant oncolytic influenza virus;

[0038] (5) Animal tissue containing the recombinant oncolytic influenza virus;

[0039] (6) Animal organs containing the recombinant oncolytic influenza virus

[0040] Among the above-mentioned biological materials, the animal cells, the animal tissues and the animal organs do not include propagation materials.

[0041] Among the above-mentioned biological materials, the microorganisms, the animal cells, the animal tissues and the animal organs can all serve as hosts for the recombinant oncolytic viruses.

[0042] In one embodiment of the present invention, the recombinant vector containing the DNA molecule encoding the PB2-RNA in (2) is pHW2000-PB2, the recombinant vector containing the DNA molecule encoding the PA-RNA is pHW2000-PA, the recombinant vector containing the DNA molecule encoding the PB1-CCL19-RNA is pHW2000-PB1-CCL19, the recombinant vector containing the DNA molecule encoding the NP-RNA is pHW2000-NP, the recombinant vector containing the DNA molecule encoding the NA-RNA is pHW2000-NA, the recombinant vector containing the DNA molecule encoding the HA-RNA is pHW2000-HA, the recombinant vector containing the DNA molecule encoding the M-RNA is pHW2000-M, and the recombinant vector containing the DNA molecule encoding the NS-RNA is pHW2000-NS. The pHW2000-PB1-CCL19 can express the CCL19 protein shown in Sequence 1.

[0043] In order to solve the above technical problems, the present invention also provides a drug for treating tumors, wherein the active ingredient of the drug is the recombinant oncolytic influenza virus.

[0044] The active ingredient of the above-mentioned drug can also be a composition obtained by combining the recombinant oncolytic influenza virus and other tumor treatment drugs as an active ingredient.

[0045] In order to solve the above technical problems, the present invention further provides any of the following applications:

[0046] (1) Use of the recombinant oncolytic influenza virus in the preparation of drugs for treating tumors;

[0047] (2) Use of the product in the preparation of drugs for treating tumors;

[0048] (3) Application of the biomaterial in the preparation of drugs for treating tumors;

[0049] (4) Use of the tumor treatment drug in the preparation of a tumor treatment drug;

[0050] (5) Use of the recombinant influenza virus in treating tumors;

[0051] (6) Application of the product in treating tumors;

[0052] (7) Application of the biomaterial in treating tumors;

[0053] (8) Use of the anti-tumor drug in treating tumors.

[0054] The tumors described in the present invention include colorectal cancer, but are not limited to colorectal cancer, and may also include lung cancer, breast cancer, liver cancer, melanoma, lymphoma, leukemia, ovarian cancer, cervical cancer, gastric cancer, kidney cancer, pancreatic cancer, prostate cancer, and glioma.

[0055] Experiments have shown that the recombinant oncolytic influenza virus (rFlu-PB1-CCL19) of the present invention can specifically infect tumor cells and effectively replicate in tumor cells: after the recombinant oncolytic influenza virus infects cells, the replication efficiency in colorectal cancer cells is high, while the replication efficiency in normal colorectal mucosal epithelial cells is low. The recombinant oncolytic influenza virus of the present invention has a specific killing effect on tumor cells: after the recombinant oncolytic influenza virus infects cells, the recombinant oncolytic influenza virus has a significant killing effect on colorectal cancer cells, but has no significant killing effect on normal colorectal mucosal epithelial cells. The recombinant oncolytic influenza virus of the present invention can inhibit the growth and development of tumors in animals: after treating tumor-bearing animals with recombinant oncolytic influenza virus, the growth of tumors is significantly inhibited, and even disappears, while the weight of mice is not significantly affected, and the survival of mice after treatment is significantly prolonged, proving that it has good tumor inhibition effect and safety, and can be used for the treatment of tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for describing the embodiments are briefly introduced below. The drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0057] Figure 1 The structural model diagram of the recombinant gene PB1-CCL19 of the recombinant oncolytic influenza virus rFlu-PB1-CCL19 (A: The structural diagram of the recombinant gene PB1-CCL19 after the recombinant oncolytic influenza virus PB1 gene modification. B: The simulation diagram of the mechanism of action of the recombinant oncolytic influenza virus.)

[0058] Figure 2 To identify the recombinant gene PB1-CCL19 of the recombinant oncolytic influenza virus rFlu-PB1-CCL19.A: RT-PCR identification showed that the size of the target gene was consistent with expectations; B: Gene sequencing identification showed that the sequence of the target gene was consistent with expectations.

[0059] Figure 3 To identify the genetic stability of the recombinant oncolytic influenza virus rFlu-PB1-CCL19. A: After rFlu-PB1-CCL19 was continuously passaged in chicken embryos for 5 generations, its HA hemagglutination titer remained stable; B: After rFlu-PB1-CCL19 was continuously passaged in chicken embryos for 5 generations, RT-PCR identified the recombinant gene PB1-CCL19, and its fragment size was consistent with expectations.

[0060] Figure 4 The morphology and particle size of the recombinant oncolytic influenza virus rFlu-PB1-CCL19 were identified by electron microscopy. A: Transmission electron microscopy observation of the morphology of rFlu-PB1-CCL19 showed that the virus was mostly spherical, with surface spike proteins such as HA and NA clearly visible, which was no different from the wild-type influenza A virus; B: The size distribution of rFlu-PB1-CCL19 virus particles, the virus particle size was mostly distributed between 80-120nm, which was consistent with the size of wild-type influenza A virus.

[0061] Figure 5 ELISA was used to detect the expression of the exogenous gene CCL19 of the recombinant oncolytic influenza virus rFlu-PB1-CCL19 in chicken embryos. A: ELISA detection of CCL19 expression standard curve; B: CCL19 expression levels of wild-type PR8 and rFlu-PB1-CCL19. The results showed that rFlu-PB1-CCL19 was continuously passaged for 5 generations in chickens, and the expression level of CCL19 remained stable.

[0062] Figure 6 To detect the HA hemagglutination titer of the recombinant oncolytic influenza virus rFlu-PB1-CCL19 after purification and concentration.

[0063] Figure 7 To identify the replication ability of recombinant oncolytic influenza virus rFlu-PB1-CCL19 in colorectal cancer. A: HA hemagglutination titer of rFlu-PB1-CCL19 and WT-PR8 after replication in HT29 cells; B: HA hemagglutination titer of rFlu-PB1-CCL19 and WT-PR8 after replication in HCT116 cells; C: HA hemagglutination titer of rFlu-PB1-CCL19 and WT-PR8 after replication in SW620 cells; D: HA hemagglutination titer of rFlu-PB1-CCL19 and WT-PR8 after replication in Lovo cells; E: HA hemagglutination titer of rFlu-PB1-CCL19 and WT-PR8 after replication in CCD841 cells; F: HA hemagglutination titer of rFlu-PB1-CCL19 and WT-PR8 after replication in CT26 cells.

[0064] Figure 8To identify the inhibitory effect of recombinant oncolytic influenza virus rFlu-PB1-CCL19 on the proliferation of colorectal cancer cells. A: The inhibitory effect of rFlu-PB1-CCL19 and WT-PR8 on HT29 cell viability; B: The inhibitory effect of rFlu-PB1-CCL19 and WT-PR8 on HCT116 cell viability; C: The inhibitory effect of rFlu-PB1-CCL19 and WT-PR8 on SW620 cell viability; D: The inhibitory effect of rFlu-PB1-CCL19 and WT-PR8 on Lovo cell viability; E: The inhibitory effect of rFlu-PB1-CCL19 and WT-PR8 on CCD841 cell viability; F: The inhibitory effect of rFlu-PB1-CCL19 and WT-PR8 on CT26 cell viability.

[0065] Fig. 9 To identify the chemotactic effect of the culture supernatant on immune cells RAW264.7 after CT26 cells were infected with the recombinant oncolytic influenza virus rFlu-PB1-CCL19. A: The lower chamber of the control group; B: The lower chamber of the WT-PR8 group; C: The lower chamber of the rFlu-PB1-CCL19 group; D: Statistical analysis of the number of cells in the lower chamber of each group.

[0066] Fig.10 The following is a graph showing the changes in body weight and tumor volume of tumor-bearing mice after 21 days of treatment with the recombinant oncolytic influenza virus rFlu-PB1-CCL19. A: Changes in body weight of mice in each group on Day 21; B: Changes in tumor volume of mice in each group on Day 21.

[0067] Fig.11 This is a physical picture of tumor tissue 21 days after treatment with recombinant oncolytic influenza virus rFlu-PB1-CCL19.

[0068] Fig.12 Diagnostic images of HE in various tissues of mice 21 days after treatment with recombinant oncolytic influenza virus rFlu-PB1-CCL19.

[0069] Fig.13 This is the survival curve of tumor-bearing mice. DETAILED DESCRIPTION

[0070] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, but not for limiting the scope of the present invention.

[0071] Example 1. Rescue and identification of recombinant oncolytic influenza viruses

[0072] The present invention provides a recombinant oncolytic influenza virus, named rFlu-PB1-CCL19, which expresses a protein named chemokine CCL19. CCL19 is a protein whose amino acid sequence is sequence 1 and is encoded by nucleotides 2422-2652 in sequence 2.

[0073] 1. Construction of recombinant bidirectional expression plasmid pHW2000-PB1-CCL19

[0074] According to the structure of the recombinant gene fragment PB1-CCL19 shown in the abstract diagram and sequence 2, the corresponding DNA molecule was artificially synthesized, and the DNA molecule and the bicistronic vector pHW2000 were linearized. The recombinant gene fragment and the vector pHW2000 fragment were connected using the InFusion kit to construct the target recombinant plasmid pHW2000-PB1-CCL19. The target plasmid obtained by homologous recombination was transformed into Escherichia coli DH-5α competent cells for plasmid amplification, and the recombinant plasmid was identified and screened by PCR, agarose gel electrophoresis and gene sequencing technology, and the plasmid concentration and purity were detected using an ultraviolet spectrophotometer.

[0075] 2. Rescue of recombinant oncolytic influenza virus

[0076] The recombinant vector pHW2000-PB2 containing the DNA molecule encoding the PB2-RNA, the recombinant vector pHW2000-PA containing the DNA molecule encoding the PA-RNA, the recombinant vector pHW2000-PB1-CCL19 containing the DNA molecule encoding the PB1-CCL19-RNA, the recombinant vector pHW2000-NP containing the DNA molecule encoding the NP-RNA, the recombinant vector pHW2000-NA containing the DNA molecule encoding the NA-RNA, the recombinant vector pHW2000-HA containing the DNA molecule encoding the HA-RNA, the recombinant vector pHW2000-M containing the DNA molecule encoding the M-RNA, and the recombinant vector pHW2000-NS containing the DNA molecule encoding the NS-RNA were co-transfected into 293T cells in the same proportions using Polyfect Reagent to obtain the culture medium supernatant containing the recombinant virus.

[0077] 3. Amplification of recombinant oncolytic influenza virus

[0078] The culture medium supernatant containing the recombinant virus is harvested and inoculated into chicken embryos for virus amplification, and the allantoic fluid containing the virus particles is harvested and concentrated and purified by sucrose density gradient centrifugation.

[0079] 4. Biological characteristics and functional identification of recombinant oncolytic influenza viruses

[0080] (1) Sequence identification of the harvested rFlu-PB1-CCL19 genome by RT-PCR, sequencing and other methods;

[0081] (2) The viral titer of rFlu-PB1-CCL19 was determined by hemagglutination test, TCID50 value, plaque assay and other methods;

[0082] (3) ELISA was used to detect the expression of exogenous gene CCL19 after rFlu-PB1-CCL19 was inoculated into chicken embryos and various colorectal cancer cell lines, including HT29, CT26, HCT116, SW620, and Lovo, and the function of CCL19 in attracting immune cells, such as T cells, DCs, NK cells, and macrophages, was verified by Transwell assay;

[0083] (4) RT-PCR was used to detect the viral proliferation dynamics after rFlu-PB1-CCL19 was inoculated into normal human colorectal mucosal epithelial cells CCD841 and various colorectal cancer cells;

[0084] (5) After rFlu-PB1-CCL19 was inoculated into chicken embryos and various colorectal cancer cells, it was continuously passaged for at least 5 generations, and the genome sequence and CCL19 expression of each generation of the virus were detected to determine the genetic stability of rFlu-PB1-CCL19;

[0085] (6) The particle size and morphological structure of rFlu-PB1-CCL19 were observed by transmission electron microscopy.

[0086] Example 2: Study on the oncolytic effect and mechanism of recombinant oncolytic influenza virus in vitro

[0087] 1. Study on the oncolytic effect of recombinant oncolytic influenza virus in vitro

[0088] (1) rFlu-PB1-CCL19 infected colon cancer cell lines: HT29, CT26, HCT116, SW620, after Lovo, the killing effect of rFlu-PB1-CCL19 on colorectal cancer cells was preliminarily determined by observing cytopathic effect (CPE);

[0089] (2) Verify the effect of rFlu-PB1-CCL19 on the proliferation activity of colorectal cancer cells through MTT, CellTiter-Glo and other experimental studies;

[0090] (3) Flow cytometry and Annexin V / PI double staining were used to detect the necrosis and apoptosis ratios of tumor cells;

[0091] (4) The scratch assay was used to detect the migration of tumor cells after infection with rFlu-PB1-CCL19. The normal human colorectal mucosal epithelial cell line CCD841 was used as a control in the above experiments to study the tumor targeting and oncolytic effects of rFlu-PB1-CCL19 in vitro.

[0092] 2. Study on the oncolytic mechanism of recombinant oncolytic influenza virus in vitro

[0093] (1) After rFlu-PB1-CCL19 infected various colorectal cancer cells, the expression and secretion levels of CCL19 were detected by ELISA;

[0094] (2) The ability of CCL19 to attract T cells, DCs, NK cells, and macrophages was verified by Transwell assay;

[0095] (3) RT-qPCR, Western Blot, etc. were used to detect the expression of CCR7 on the surface of tumor cells, the expression of apoptosis molecule markers Bid and Bax, and the content of Caspase 3 and PARP spliceosomes. After using anti-CCL19 antibody to block the specific binding of CCL19 / CCR7, the changes in the content of apoptosis molecule markers and spliceosomes were detected to evaluate the activation of the extrinsic apoptosis pathway by CCL19 / CCR7 specific binding.

[0096] Example 3: Study on the oncolytic effect and mechanism of recombinant oncolytic influenza virus in vivo

[0097] 1. Study on the oncolytic effect of recombinant oncolytic influenza virus in vivo

[0098] (1) Establish a subcutaneous transplant tumor model of Balb / C mouse colorectal cancer cell line CT26, inject RFLU-PB1-CCL19 into the tumor, and evaluate the effectiveness of RFLU-PB1-CCL19 in inhibiting the growth and metastasis of colorectal cancer by measuring and drawing tumor growth curves, calculating tumor inhibition rates, and performing histopathological and immunohistochemical examinations of major organs;

[0099] (2) The targeting and safety of RFLU-PB1-CCL19 were evaluated by measuring the weight of mice, drawing survival curves, detecting the biological distribution of the virus in mice by RT-qPCR, and pathologically detecting the damage to important tissues and organs.

[0100] 2. Study on the oncolytic mechanism of recombinant oncolytic influenza virus in vivo

[0101] (1) Western Blot was used to detect the expression level of CCL19 in tumor tissues;

[0102] (2) Histopathology, immunohistochemistry, multicolor immunofluorescence, etc. were used to detect the infiltration of T cells, DCs, NK cells, and macrophages in the tumor microenvironment; RT-qPCR, Western Blot, etc. were used to detect the expression and secretion levels of immune cell effector molecules such as granzyme B, perforin, IFN-γ, and IL-2 in the tumor microenvironment to evaluate the activation of immune cells in the tumor microenvironment;

[0103] (3) Flow cytometry was used to detect the phenotypes of immune cells such as T cells, DCs, NK cells, and macrophages in the spleen of mice to evaluate the ability of RFLU-PB1-CCL19 to regulate the body's tumor-specific immune response;

[0104] (4) Through single-cell genome sequencing and bioinformatics analysis, we enriched the signaling pathways of RFLU-PB1-CCL19, analyzed the cellular interactions between tumor cells and cellular components in the tumor microenvironment, and biologically verified its function of inhibiting tumor growth, invasion, and metastasis.

[0105] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0106] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

Claims

1. A recombinant oncolytic influenza virus, characterized in that: The recombinant oncolytic influenza virus is an influenza virus expressing the chemokine CCL19 protein, and its PB1 gene is transformed into a recombinant gene PB1-CCL19; The CCL19 protein is a protein whose amino acid sequence is SEQ ID NO: 1; The recombinant gene PB1-CCL19 is a nucleotide sequence recombinant gene; the genome of the recombinant oncolytic influenza virus is composed of 8 single-stranded negative-stranded, segmented RNAs, and the negative-strand RNA of the recombinant oncolytic influenza virus transcribes a set of positive-strand RNAs complementary to the negative-strand RNAs, and the set of positive-strand RNAs includes PB2-RNA, PA-RNA, PB1-CCL19-RNA, NP-RNA, NA-RNA, HA-RNA, M-RNA, and NS-RNA; The PB2-RNA is a positive-strand RNA encoding the PB2 gene in the influenza virus strain; The PA-RNA is a positive-strand RNA encoding the PA gene in the influenza virus strain; The PB1-CCL19-RNA is a positive-strand RNA encoding the recombinant gene PB1-CCL19; The NP-RNA is a positive-strand RNA encoding the NP gene in the influenza virus strain; The NA-RNA is a positive-strand RNA encoding the NA gene in the influenza virus strain; The HA-RNA is a positive-strand RNA encoding the HA gene in the influenza virus strain; The M-RNA is a positive-strand RNA encoding the M gene in the influenza virus strain; The NS-RNA is a positive-strand RNA encoding the NS gene in the influenza virus strain; The structure of the recombinant gene PB1-CCL19 is that a hydrolyzable linker T2A nucleotide sequence, a CCL19 signal peptide nucleotide sequence, a CCL19 nucleotide sequence, and a packaging signal nucleotide sequence at the 5'NCR end of the PB1 gene are sequentially inserted from 5' to 3' before the termination codon at the 5'NCR end of the PB1 gene in the influenza virus strain, and other nucleotides remain unchanged; the influenza virus strain is influenza A virus.

2. The method for constructing and rescuing a recombinant oncolytic influenza virus according to claim 1, characterized in that: A recombinant vector containing a DNA molecule encoding the PB2-RNA, a recombinant vector containing a DNA molecule encoding the PA-RNA, a recombinant vector containing a DNA molecule encoding the PB1-CCL19, a recombinant vector containing a DNA molecule encoding the NP-RNA, a recombinant vector containing a DNA molecule encoding the NA-RNA, a recombinant vector containing a DNA molecule encoding the HA-RNA, a recombinant vector containing a DNA molecule encoding the M-RNA, and a recombinant vector containing a DNA molecule encoding the NS-RNA are introduced into packaging cells to obtain a recombinant oncolytic influenza virus; the vector is a pHW2000 plasmid.

3. A drug for treating colorectal cancer, wherein the active ingredient is the recombinant oncolytic influenza virus according to claim 1.

4. Use of the recombinant oncolytic influenza virus according to claim 1 in the preparation of a drug for treating colorectal cancer.